Vertex Pharmaceuticals 주식 (NASDAQ: VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) 주식

VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

McDonald's Launches Limited-Edition Holiday Cups Co-Branded With Doodles

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

VOXX

VRTX

월요일(10일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. 맥도날드, 온 세미컨덕터, 복스 인터내셔널, 로크웰 및 버텍스

월요일 주목해야 할 주식: 맥도날드, 온 세미컨덕터, 복스 인터내셔널, 로크웰 및 버텍스

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Health Care

Technicals

General

버텍스 파마슈티컬스(NASDAQ:VRTX)는 주가가 악성 데스 크로스(Death Cross)를 형성하면서 하락세 기술 신호를 받고 있다.

버텍스의 주가는 데스 크로스를 형성한 약세 차트와 힘겨루기 중

arm-qualcomm-shutter

Large Cap

Movers

CTAS

CVNA

MNDY

MSTR

PAYC

QCOM

SMCI

이들 11개 대형주들은 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 노보 노디스크 A/S(NYSE:NVO)의 주식이 20.52% 하락했다. 이는 회사가 REDEFINE 1의 3상 시험 주요 결과를 발표한 후 발생한 일이다.

노보 노디스크, 버텍스 및 Arm은 지난주 최악의 성과를 보인 11개 대형주 중 일부 (12월 16-20일)

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 4.67% since its last report. The company recently reported that it has 5.75 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743529515_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.52%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Vertex Pharmaceuticals Gaining or Losing Market Support?

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $408 to $420.

Price Target

Analyst Ratings

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $420

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high estimate of $567.00, and a low estimate of $407.00. This upward trend is apparent, with the current average reflecting a 0.91% increase from the previous average price target of $473.82.
<img src="https://www.benzinga.com/files/images/story/2025/1743458443_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Vertex Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$567.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$408.00</td>
<td>$407.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$424.00</td>
<td>$408.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$520.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$407.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$450.00</td>
<td>$433.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$467.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$459.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$433.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$460.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$533.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$460.00</td>
<td>$555.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vertex Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Vertex Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Vertex Pharmaceuticals Better</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Vertex Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 15.66%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 31.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.7%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Vertex Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.08%, the company showcases efficient use of assets and strong financial health.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) announced on Friday updates about its type 1 diabetes (T1D) portfolio.
The company said it would not be advancing further in VX-264 clinical trials. Vertex plans to conduct further analyses, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44545391/vertex-announces-program-updates-for-type-1-diabetes-portfolio" rel="noreferrer noopener">including of explanted devices</a>.
<ul>
<li>Vertex completed enrollment and dosing in Parts A and B of the&nbsp;Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B.</li>
<li>In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immunoprotective device.</li>
<li>In Part B, there were two primary endpoints: safety and change in peak C-peptide during a mixed-meal tolerance test (MMTT) from baseline at Day 90.</li>
<li>VX-264 was generally safe and well tolerated; however, the study did not meet the efficacy endpoint.</li>
<li>Increases in C-peptide, a marker of insulin production, were not observed at levels necessary to deliver benefit.</li>
</ul>
Zimislecel (formerly VX-880), Vertex&#8217;s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia.
<ul>
<li>The is on track to complete enrollment and dosing in the first half of 2025, setting up global regulatory submissions in 2026.</li>
</ul>
Vertex is investing in expanding its manufacturing and commercial capabilities to ensure launch readiness. If approved, eligible patients across the U.S. and Europe with recurrent SHEs despite best available care could benefit from zimislecel. Vertex anticipates that initial approval could serve approximately 60,000 people with severe T1D.
Vertex is also pursuing research-stage T1D programs. These approaches include alternative immunosuppressive regimens, gene-edited hypoimmune stem-cell derived islet cell therapies, and novel devices to encapsulate islet cells.
William Blair wrote,&#8221;We view the discontinuation of VX-264 as disappointing given that this would have expanded Vertex's type 1 diabetes market significantly from that being addressed from zimislecel; however, we did not ascribe any value for the early-stage program in our model. Vertex's prioritization on the clinical advancement and potential launch of zimislecel for 60,000 severe T1D patients is prudent given the positive data to date, and approval in the T1D space would serve to further the company's diversity of commercial assets beyond cystic fibrosis and acute pain.&#8221;
Analyst Myles Minter reiterated <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings" target="_blank" rel="noreferrer noopener">an Outperform rating</a>.
VRTX Price Action: Vertex stock was down 2.09% at $482.36 at publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44566809/eli-lillys-cholesterol-drug-reduces-genetic-heart-disease-risk-factor-by-93-9" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data

B of A Securities analyst Ying Huang maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and raises the price target from $555 to $567.

B of A Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $567

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement -
- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 -
- Continue to progress multiple novel, research-stage immunoprotective approaches -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vrtx.com%2F&amp;esheet=54230222&amp;newsitemid=20250328622122&amp;lan=en-US&amp;anchor=Vertex+Pharmaceuticals+Incorporated&amp;index=1&amp;md5=8b0996d221294fdf9df4f4bb3c2785ac">Vertex Pharmaceuticals Incorporated</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) today announced several updates on the Company's type 1 diabetes (T1D) portfolio.

Vertex Announces Program Updates For Type 1 Diabetes Portfolio; VX-264 Phase 1/2 Enrollment And Dosing Complete In Parts A And B: VX-264 Was Generally Safe And Well Tolerated; Efficacy Data Are Not Supportive Of Further Clinical Advancement

On CNBC's <a href="https://www.cnbc.com/video/2025/03/26/final-trades-chewy-wabtec-crown-castle-and-jpmorgan-chase.html">&#8220;Halftime Report Final Trades</a>,&#8221; Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous for the short term on Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>).
RBC Capital analyst Brian Abrahams, on Feb. 20, maintained Vertex Pharmaceuticals with a Sector Perform rating and raised the price target from<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings"> $407 to $408</a>.
Shannon Saccocia of NB Private Wealth named iShares U.S. Financials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYF#NYSE">IYF</a>) as her final trade.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joshua Brown of Ritholtz Wealth Management picked Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), saying the stock is close to its 52-week high.
Supporting his view, MoffettNathanson analyst Michael Nathanson, on March 17, upgraded Netflix from Neutral to Buy and raised the price target from $850 to $1100.
Price Action:
<ul>
<li>Vertex Pharmaceuticals shares gained 0.5% to close at $502.55 on Thursday.</li>
<li>iShares U.S. Financials ETF fell 0.6% during Thursday's session.</li>
<li>Netflix shares gained 0.6% to close at $976.72 on Thursday.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock"> Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a></li>
</ul>
Photo: Shutterstock

Media

iShares Dow Jones US Financial Sector Index Fund

NFLX

Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Vertex Pharmaceuticals, Netflix, iShares U.S. Financial ETF

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 20 years by 13.98% on an annualized basis producing an average annual return of 22.16%. Currently, Vertex Pharmaceuticals has a market capitalization of $129.85 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $5,245.54 today based on a price of $505.67 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742570109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 5 years by 2.37% on an annualized basis producing an average annual return of 19.23%. Currently, Vertex Pharmaceuticals has a market capitalization of $130.20 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a price of $507.02 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741896013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today

Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VRTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Vertex Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $76,828, and 8 are calls, for a total amount of $594,591.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $380.0 and $600.0 for Vertex Pharmaceuticals, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $380.0 to $600.0 in the last 30 days. 
<h3>Vertex Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741893347_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$100.0</td>
<td>$91.0</td>
<td>$93.7</td>
<td>$480.00</td>
<td>$159.2K</td>
<td align="right">76</td>
<td align="right">17</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$175.7</td>
<td>$171.0</td>
<td>$171.0</td>
<td>$400.00</td>
<td>$136.8K</td>
<td align="right">66</td>
<td align="right">0</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$34.7</td>
<td>$34.0</td>
<td>$34.0</td>
<td>$500.00</td>
<td>$125.8K</td>
<td align="right">473</td>
<td align="right">6</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$68.3</td>
<td>$62.2</td>
<td>$64.0</td>
<td>$450.00</td>
<td>$64.0K</td>
<td align="right">206</td>
<td align="right">0</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$45.6</td>
<td>$42.0</td>
<td>$42.01</td>
<td>$510.00</td>
<td>$50.4K</td>
<td align="right">16</td>
<td align="right">12</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Current Position of Vertex Pharmaceuticals</h3>
<ul>
<li>Trading volume stands at 1,034,376, with VRTX's price up by 1.51%, positioned at $502.93.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 53 days.</li>
</ul>
<h3>What The Experts Say On Vertex Pharmaceuticals</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $416.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Vertex Pharmaceuticals, which currently sits at a price target of $408. 
&#x2A; Showing optimism, an analyst from Canaccord Genuity upgrades its rating to Hold with a revised price target of $424. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Vertex Pharmaceuticals options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics

COWZ

IBKR

CNBC Halftime Report Final Trades: Netflix, Meta Platforms, Vertex Pharmaceuticals, Interactive Brokers Group, Pacer US Cash Cows 100 ETF

As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">2Seventy Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>)</h3>
<ul>
<li>On March 10, 2seventy bio agreed to be acquired by Bristol Myers Squibb for $5.00 per share in 88% premium transaction valued at $286 million. &#8220;A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living with multiple myeloma and maximizing value for all stakeholders,&#8221; said Chip Baird, chief executive officer, 2seventy bio. &#8220;The strategic rationale for this acquisition is clear and today&#8217;s announcement represents the culmination of the journey for 2seventy bio." The company's stock gained around 20% over the past month and has a <a href="https://www.benzinga.com/quote/TSVT">52-week high of $5.99</a>.</li>
<li>RSI Value: 82.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TSVT Price Action: Shares of 2Seventy Bio gained 5.3% to close at $2.80 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)</h3>
<ul>
<li>On Feb. 14, the FDA approved Sanofi's Merilog as a biosimilar to Novo Nordisk A/S‘ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Novolog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes mellitus.. The company's stock gained around 10% over the past month and <a href="https://www.benzinga.com/quote/SNY">has a 52-week high</a> of $60.12.</li>
<li>RSI Value: 77.4</li>
<li>SNY Price Action: Shares of Sanofi gained 0.2% to close at $59.35 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)</h3>
<ul>
<li>On Feb. 10, Vertex Pharmaceuticals posted better-than-expected quarterly sales. &#8220;2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch of our fifth CF medicine, ALYFTREK; the continuing global launch of CASGEVY; and multiple ongoing pivotal trials. We are excited to drive diversification of the revenue base, disease areas of focus, R&amp;D pipeline, and geographies to continue to deliver long-term value to both patients and shareholders,&#8221; said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. The company's stock gained around 10% over the past month and has a <a href="https://www.benzinga.com/quote/VRTX">52-week high </a>of $519.88.</li>
<li>RSI Value: 74</li>
<li>VRTX Price Action: Shares of Vertex Pharmaceuticals gained 2.4% to close at $500.01 on Monday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44218016/top-3-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 3 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>

TSVT

Top 3 Health Care Stocks That May Keep You Up At Night In Q1

In January, the Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) Journavx, a non-opioid oral pain signal <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">inhibitor for acute pain</a>.
This marked the first approval of a new class of pain medication in more than 20 years, offering an alternative to <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43404756/fda-approves-first-non-opioid-pain-pill-as-medical-marijuana-remains-a-proven-alternative-for-relief" rel="noreferrer noopener">traditional opioid treatments</a>.
According to the Formulary Update released in February, Journavx has been <a target="_blank" href="https://www.optum.com/content/dam/noindex-resources/consumers/pdfs/forms/PharmacyPassages_Direct%20and%20UMR_February_2025.pdf" rel="noreferrer noopener">placed</a> on Tier 3 of Optum Rx Premium and Select Formularies and is being further evaluated by the Optum Rx National Pharmacy &amp; Therapeutics Committee for clinical value and safety. Many Tier 3 drugs have lower-cost options in Tier 1 or 2.
Optum Rx, is the pharmacy benefit manager owned by UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43038618/hhs-challenges-vertex-over-fertility-services-program-tied-to-casgevy-gene-therapy" rel="noreferrer noopener">HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is &#8216;Grasping at Straws&#8217;</a>
According to Bloomberg, the interim decision ensures the drug will be covered, but patients may pay more since it&#8217;s not in the lower-cost tiers, which usually include generics or preferred brand drugs. This applies to Optum Rx&#8217;s Premium and Select formularies for commercial plans.
&#8220;With the growing concern over opioid use disorder, new non-opioid alternatives such as Journavx provide additional options for treatment,&#8221; the document says.
Citing a BMO Capital Markets analyst, the Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-03-06/vertex-non-opioid-pain-drug-gets-some-unitedhealth-coverage?sref=TBDibEcD" rel="noreferrer noopener">report</a> notes that a less favorable formulary placement will likely make it harder for some patients to access the medication. The report also notes a challenge Vertex will face: convincing insurers to cover its drug, which costs much more than opioids. The wholesale price is $15.50 per 50 mg tablet taken twice daily.
Concurrently, the UK Medicines and Healthcare products Regulatory Agency (MHRA) <a href="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-uk-mhra-approval-alyftrekr" target="_blank" rel="noreferrer noopener">approved</a> Vertex&#8217;s Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination therapy for cystic fibrosis patients ages 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene.
In February, Vertex Pharmaceuticals reported fourth-quarter earnings per share of $3.50, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $3.57</a>.
Sales reached $2.91 billion, up 16% year over year, beating the consensus of $2.78 billion. Annual sales <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43607732/vertex-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">reached $11.20 billion</a>.
Vertex expects 2025 sales of $11.75 billion-$12 billion versus a consensus of $11.84 billion.
Price Action: VRTX stock is up 0.32% at $487.26 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44194539/eli-lillys-single-monthly-maintenance-shot-of-eczema-drug-shows-completely-clear-skin-at-3-years-in-50-of-trial-patients" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients</a></li>
</ul>

Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies

A new compound that provides the pain-relieving <a href="https://www.benzinga.com/markets/cannabis/24/01/36578723/huge-study-reveals-cannabis-provides-similar-pain-relief-benefits-as-opioids-without-negative-co">properties of cannabis</a> without the mind-altering effects can serve as an effective alternative to opioids for pain relief, according to researchers who developed the compound that mimics a natural molecule found in the cannabis plant.
Researchers from Washington University School of Medicine in St. Louis and Stanford University found the compound harnesses the pain-relieving properties of cannabis without causing addiction in mice.
"There is an urgent need to develop non-addictive treatments for chronic pain, and that's been a major focus of my lab for the past 15 years," said lead author Susruta Majumdar, Ph.D of Washington University School of Medicine.
"The custom-designed compound we created attaches to pain-reducing receptors in the body but by design, it can't reach the brain. This means the compound avoids psychoactive side effects such as mood changes and isn't addictive because it doesn't act on the brain's reward center," Majumdar said.
The <a href="https://www.nature.com/articles/s41586-025-08618-7">findings</a>, published in the journal Nature on March 5, showed that in both mouse models, injections of the modified compound eliminated touch hypersensitivity.
Majumdar, a professor of anesthesiology, explained in a Washington University <a href="https://medicine.washu.edu/news/compound-harnesses-cannabis-pain-relieving-properties-without-side-effects/">press release</a> that opioids dull the sensation of pain in the brain and hijack the brain's reward system, triggering the release of dopamine and feelings of pleasure, which make opioids so addictive.
Government surveys show analgesics, or medications that control pain, are the most commonly prescribed type of drug in hospitals. And, <a href="https://www.cdc.gov/nchs/products/databriefs/db491.htm">according</a> to the Centers for Disease Control drug overdoses related to opioids, including <a href="https://www.benzinga.com/topic/fentanyl">fentanyl</a> are among the leading causes of accidental death in the U.S. In 2022, some 82,000 deaths in the U.S. were linked to opioids.
"For millennia, people have turned to marijuana as a treatment for pain. Clinical trials also have evaluated whether cannabis provides long-term pain relief," said co-corresponding study author Professor Robert Gereau of Washington University&#8217;s Medicine Pain Center.
&#8220;But inevitably the psychoactive side effects of cannabis have been problematic, preventing cannabis from being considered as a viable treatment option for pain. However, we were able to overcome that issue," Gereau added.
Approximately 125 million opioid prescriptions were dispensed&nbsp;to American patients in 2023 to treat moderate to severe pain, <a href="https://www.cdc.gov/overdose-prevention/about/prescription-opioids.html#:~:text=Approximately%20125%20million%20opioid%20prescriptions">according</a> to the CDC.
In January 2025, the U.S. Food and Drug Administration <a href="https://www.benzinga.com/general/health-care/25/01/43404756/fda-approves-first-non-opioid-pain-pill-as-medical-marijuana-remains-a-proven-alternative-for-relief">approved</a> the first new pain reliever to hit the market in more than 20 years. This medication, produced by Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), is a non-opioid and therefore non-addictive. 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44166646/fda-approves-ars-pharmaceuticals-lower-dose-neffy-nasal-spray-for-emergency-allergy-treatment">FDA Approves ARS Pharmaceuticals&#8217; Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment</a></li>
</ul>
Photo: Shutterstock

Cannabis

Cannabis For Pain Relief: Scientists Develop New Compound Without Mind-Altering Effects — Alternative To Opioids?

Live On CNBC, Rob Sechan Announces Sold Vertex Pharmaceuticals

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$48.00</td>
<td>$81.9K</td>
<td>541</td>
<td align="right">474</td>
</tr>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$380.00</td>
<td>$74.5K</td>
<td>42</td>
<td align="right">88</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$295.00</td>
<td>$34.6K</td>
<td>148</td>
<td align="right">31</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$26.3K</td>
<td>2.6K</td>
<td align="right">26</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$110.00</td>
<td>$25.4K</td>
<td>86</td>
<td align="right">25</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$300.00</td>
<td>$91.7K</td>
<td>3</td>
<td align="right">15</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$960.00</td>
<td>$120.4K</td>
<td>79</td>
<td align="right">10</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$480.00</td>
<td>$27.2K</td>
<td>1.1K</td>
<td align="right">9</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$280.00</td>
<td>$32.2K</td>
<td>2</td>
<td align="right">6</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$590.00</td>
<td>$26.2K</td>
<td>7</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with neutral sentiment. It expires in 50 day(s) on April 17, 2025. Parties traded 200 contract(s) at a $48.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $81.9K, with a price of $410.0 per contract. There were 541 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• For MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we notice a call option sweep that happens to be bearish, expiring in 50 day(s) on April 17, 2025. This event was a transfer of 25 contract(s) at a $380.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $74.5K, with a price of $2970.0 per contract. There were 42 open contracts at this strike prior to today, and today 88 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be neutral, expiring in 2 day(s) on February 28, 2025. This event was a transfer of 25 contract(s) at a $295.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $1387.0 per contract. There were 148 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be neutral, expiring in 324 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $1315.0 per contract. There were 2612 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with neutral sentiment. It expires in 79 day(s) on May 16, 2025. Parties traded 25 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $1020.0 per contract. There were 86 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with neutral sentiment. It expires in 2 day(s) on February 28, 2025. Parties traded 5 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $91.7K, with a price of $18346.0 per contract. There were 3 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bearish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $960.00 strike. The total cost received by the writing party (or parties) was $120.4K, with a price of $12040.0 per contract. There were 79 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 5 contract(s) at a $480.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $5455.0 per contract. There were 1141 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bearish sentiment. It expires in 387 day(s) on March 20, 2026. Parties traded 6 contract(s) at a $280.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $5383.0 per contract. There were 2 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bullish, expiring in 688 day(s) on January 15, 2027. This event was a transfer of 5 contract(s) at a $590.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $5258.0 per contract. There were 7 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MDGL

SRPT

TGTX

10 Health Care Stocks Whale Activity In Today's Session

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 3.51% since its last report. The company recently reported that it has 4.56 million shares sold short, which is 1.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740503726_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 5.44%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a market capitalization of $123.81 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 15 years ago, it would be worth $1,163.65 today based on a price of $482.16 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740427214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years

Press Releases

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Economics

Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

AM Best Assigns Credit Ratings to Torreyana Insurance Company, Inc.

Vertex to Participate in Upcoming March Investor Conferences

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Vertex Announces Program Updates for Type 1 Diabetes Portfolio

ALNY

COEP

IMGN

REGN

RPRX

SMMT

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

Comments

Vertex Pharmaceuticals

뉴스

파트너 / 기고자

벤징가 글로벌